prenatal testing and screening. lecture outline 1.definitions 2.age related risks 3.etiology and...
TRANSCRIPT
Prenatal Testing And Screening
Lecture Outline
1. Definitions
2. Age related risks
3. Etiology and phenotype of chromosome anomalies
4. Risks, phenotype and testing options of ONTD
5. 1st and 2nd Trimester Prenatal Testing Options
6. 1st and 2nd Trimester MS Screening Options
7. New approaches to combining these tools
8. Ultrasound as a screening tool
Testing Defined
A procedure that (in most cases) provides adefinitive answer to the question that is beingasked. Tests that have low false positives andnegatives are considered diagnostic.
In the case of prenatal testing there is a risk ofmiscarriage associated with all the currentlyavailable diagnostic invasive tests.
Screening Defined• Identify those at increased risk who are
not be perceived to be at risk
• Does not dx definitively
• Follow-up options available for definitive information
• Sensitivity=True positives/all affected
• Specificity=True negatives/all unaffected
Baseline Risk for Having a Child With a
Serious Birth Defect
3-5%
WE DON’T GET BETTER WITH AGE
Maternal
Age
DS RiskBirth
All Chrom AbnBirth
DS risk Mid trimester
20 1/1231
30 1/185 1/384 1/685
33 1/592 1/285 1/452
34 1/465 1/243 1/352
35 1/385 1/178 1/274
36 1/287 1/149 1/213
37 1/225 1/123 1/166
38 1/177 1/105 1/129
39 1/139 1/80 1/100
40 1/109 1/63 1/80
41 1/85 1/48 1/61
NORMAL MALE KARYOTYPE 46,XY
NORMAL FEMALE KARYOTYPE 46, XX
WHEN MEIOSIS FAILS
Normal Sex cell production
Monosomy
Non-disjunction
Sex Cells
Sex Cells
T21 Tid Bits• ~70% T21 due to an error in maternal meiosis I
• ~ 20% maternal meiosis II
• ~ 5% occur during spermatogenesis (meiosis II)
• 5% of trisomic 21 error in mitosis
– no advanced maternal age and there is no preference for which chromosome 21 is duplicated in the mitotic error
• most common chromosomal abnormalities in liveborn children
~1/700
Phenotype• Moderate mental retardation
• Characteristic facies – upslanting palpebral fissures – epicanthic folds, – midface hypoplasia, – macroglossia
• Congenital malformations
– heart (30-40%), atrioventricular canal – gastrointestinal tract, such as duodenal stenosis or atresia,
imperforate anus, and Hirschsprung disease – Leukemia (both ALL and AML) 10-20x– acute megakaryocytic leukemia occurs 200 to 400 times
more frequently in the Down syndrome – 90% have significant hearing loss, usually of the
conductive type
Trisomy 18, Edward syndrome
1/8000
Facial•microcephaly with prominent occiput •narrow bifrontal diameter •short palpabral fissures •low-set malformed ears •cleft lip +/- palate •narrow palatal arch •micrognathia Skeletal•neck •webbed •chest •short sternum •widely spaced nipples •hips: •small pelvis, congenital dislocation of the hips, limited hip abduction •extremities: •phocomelia •rockerbottom feet or equinovarus short dorsiflexed big toes fixed flexion deformity of the fingers (overlapping of the 2nd and 5th fingers over the 3rd and 4th fingers) simple arch pattern of the fingers and toes hypoplasia of fingernails single crease of 5th finger or all fingers (absence of interphalangeal flexion creases) simian crease
Central Nervous Systemsevere mental retardation hypotonia -> hypertonia neural tube defects poor suck and weak cry failure to thrive ocular anomalies Respiratory•apnea Cardiovascular( >95%)•major: VSD, ASD, PDA •minor: transposition, ToF, coarctation, anomalous coronary artery, dextrocardia, •aberrant subclavian artery, arteriosclerosis, PS, bicuspid aortic and/or pulmonic valves Gastrointestinal•inguinal, umbilical, and/or diaphragmatic hernia •congenital defects: •diastasis recti, heterotopic pancreas, malrotation, Meckel's, tracheoesophageal fistula Genitourinary•cryptorchidism •congenital defects: double ureter, ectopic kidney, horseshoe kidney, hydronephrosis, polycystic kidney
Trisomy 18
47,XXY
• T13 Patau syndrome• 1/5,000
•severe mental retardation •coloboma, •(a cleft palate) and/or a cleft lip •hypotonia •skeletal abnormalities (polydactyly)•Renal heart defects•holoprocencephaly
Kleinfelter syndrome
1/1000
45, X
45, X
Miscarriage Turner syndrome1/3000 liveborns
Neural Tube Defects
• Second most common major congenital defect (1-2/1000)
• Not a chromosome anomaly
• Routinely tested and screened for in pregnancy
• Failure neural tube to close at 28 days gestation
• 20% are closed lesions and difficult to detect prenatally
Open Neural Tube Defects
Closed lesions
Open lesions
In 1976 the American College ofObstetrics and Gynecology
recommendedprenatal diagnosis be offered toall women 35 years of age and older atdelivery.
INDICATIONS FOR PRENATAL DIAGNOSIS
Maternal age > 35 years at EDC
Abnormal maternal serum screening for: DS cut off > 1/270 Increased risk Trisomy 18 or 13
Smith-Lemli-Opitz syndrome ONTD
Previous child with chromosomal abnormality or diagnosable genetic disorder
Balanced translocation carrier
Ultrasound anomaly (soft sign vs frank anomaly)
PRENATAL DIAGNOSTIC PROCEDURES
AMNIOCENTESIS
CHORIONIC VILLUS SAMPLING
PERCUTANEOUS UMBILICAL CORD SAMPLING
PERFORMED ROUTINELY 16-20 WEEKS
AMNIOCENTESIS
ULTRASOUND GUIDED AMNIOCENTESIS
Amniocentesis Testing
• Chromosome analysis
• AF-AFP levels• Acetylcholinesterase
• Risk of miscarriage associated with procedure 1/100-1/400
ONTD
Advantages
• Highly reliable results 99+%• Familiar• Long standing reputation• NTD detection
Disadvantages• Late in gestation
– Decision making– Privacy– Mom feels movement
• Fear of needles
• Needle invades the sac
Fetus: 12 weeks gestation
Transcervical
Chorionic Villus
Sampling
Transabdominal
Performed >10 wks-13 weeks
Chromosome analysis
Risk 1/100-1/200
• trophoblastic shell cells • Syncitiotrophoblasts – poly-proliferate
tissue type=directs• cytotrophoblasts• Mesodermal core=tissue culture• frorm finger-like extensions
Disadvantages• Placental mosaicism 1% of CVS is confirmed in the fetus ~ 10-
40%
• Second trimester amniocentesis mosaicism ~ 0.1-0.3% & confirmed in a fetus up to 70% of the time.
• ?LRD risk prior to 70 days gestation (10 weeks)
• Higher loss rate
• Less access to procedure
• Higher chance of insufficient sample
• Early test=risk of sampling a fetus potentially destined to miscarry
• No ONTD testing
• More risk of vaginal bleeding
• Speculum
Benefits(1) Earlier in gestation
(2) rapidly growing cell cultures practically free of maternal
cell contamination
(3) an efficient direct method to obtain high quality metaphases from the of the syncitiotrophoblasts tissue which the fetal karyotype is defined within a few hours of chorionic villi sampling (specialty cyto techinque)
(4) is suitable for a rapid, direct diagnosis of the related metabolic diseases.
(5) placental mosaicism (trisomic rescue in fetus) can increase the risks of genetic abnormalities such as uniparental disomy
G. Simoni1, Human Genetics 1983
Fetal Blood Sampling“PUBS”
Percutaneous Umbilical Cord Sampling(PUBS)
or Cordocentesis• ~2% risk of loss• Technically difficult prior to 20 weeks • Blood disorders such as hemophilia and
anemia– Useful for detection of Rh isoimmunization of the
fetus (blood cell count and oxygen level)→erythroblastosis fetalis (HDN)
• Chromosomal abnormalities Fetal karyotype in 48 hours
• Infections such as toxoplasmosis and rubella. • The procedure is also used to perform blood
transfusions to the fetus and to administer medication directly into the fetal blood supply.
Reproductive Decision Making
RISK Fetal Aneuploidy
Procedure Related
RISK
TO TEST OR NOT TO TEST
I want to know The benefits outweigh the risks Options are desirable Because my doctor says so…..
Not sure I want to know Risks are a big worry Options stink Because my doctor says so….
So what to do what to do…………..
SECOND TRIMESTERMATERNAL ANALYTES FOR ANEUPLOID
SCREENING
FETAL
Alpha-fetoprotein- AFPEstriol- uE3
PLACENTAL
Estriol- uE3Human chorionic gonadotrophin- hCGInhibin-A
2nd Trimester MSS Overview
Used for detection of:
1. ONTD 2. Down syndrome3. trisomy 18 4. Smith-Lemli-Opitz syndrome
Second trimester MSS
AFP
HCG
uE3
Inhibin-A
ONTD DS T18 SLO
Seru
m M
ark
er
XMoM
0.7
2.1*
0.7
2.1
0.21*
0.65
0.36
0.4*
Smith Lemli Opitz Syndrome
• Defect enzyme in the conversion of 7-dehydrocholesterol to cholesterol.
• Affects 1 in 20,000 to 40,000 births • Autosomal Recessive• Mental Retardation• Slow growth• Heart defects• Facial cleft
• Screen positive women have uE3 < 0.4 MoM • ~2% baby affected• Testing AF for 7-8- dehydrocholesterol (7/8-DHC) levels
Other……..
AFP
HCG
uE3
Inhibin-A
Seru
m M
ark
er
Turner T13 Triploidy Pregnancy complications
uE3 lower than 0.1 MoM
• Increase risk for x-linked ichthyosis
ONTD screening
• Abnormal Screen MS-AFP > 2.5 MoM
• Elevated MSAFP recommendations:– Ultrasound– 90% r/o spinal lesions
100% r/o anencephaly– VWD reduced with normal scan– If MSAFP >4.0 MoM and NL U/S
offer invasive testing
Detection Rates
• Anencephaly 100% 100%• Spina Bifida 85-90% 90%
• VWD– Omphalocele70%95%– Gastroschisis90%95%
MSAFP Add Ultrasound
Screening for DS 2nd Trimester 1/270 Cut-off
• Age 20 5
• Age AFP 30 5
• Age AFP + HCG 55 5(Double)
• Age AFP+uE3+HCG 61 7 (Triple)
• Age AFP+uE3+HCG+Inhibin-A 755 (Quad)
DR% FPR%
The detection rate for Down syndromeusing the second trimester triplescreen is:
50% for women <35 y/o 88% for women >35 y/o and
~60% for all women
Quad ~75%
First Trimester Integrated Screening For
Trisomies =FIRST
•Entire analysis performed 11-13 6/7 weeks gestation
•MS free Beta hCG and PAPP-A (pregnancy associated plasma protein)
-obtained bw 9-13 weeks
•Nuchal measurement 11-13 6/7
•Maternal age
•Detection Rates:~80% Down syndrome 1/270~90% trisomy 18 1/100
Nuchal Translucency (NT)Nuchal Translucency (NT)
• Gestation 11 to 13 6/7 wksGestation 11 to 13 6/7 wks
•Mid-sagittal viewMid-sagittal view
• Fetus away from amnionFetus away from amnion
• Enlarge head & upper Enlarge head & upper thoraxthorax
• Widest part of NTWidest part of NT
First Trimester Screening
• Free beta HCG
• PAPP-A
• NT
DS T18
>3.0 mm
Down syndrome DR ~1:270 Cut-off
MA + NTMA + NT11 10%10% 71% 71%
MA + BiochemistryMA + Biochemistry33 67% 67%
MA + NT + MA + NT + BiochemistryBiochemistry2 2 5%5% >80% >80%
1. Schuchter et al. Prenatal Diagnosis 22: 211, 2002
FPR DR
2. Wapner et al. NEJM 349: 1405, 20033. 3. Spencer et al UOG 1999Spencer et al UOG 1999
Nasal bone
Recommendations 1st Trimester Nuchal >3.5
• CVS
• Targeted ultrasound evaluation 18-20
• Echocardiogram
• Residual 5-6% risk neonate may have a yet undefined genetic syndrome…
Fetal Nasal Bone• 65% DS have absent nasal bone
• General population 1% – African Americans 8%-10%
• Secondary screen
• Difficult to obtain
• Higher false positive in 1st
Integrated Screening
PAPP-A and Nuchal
Quad Screen
Screen Positive1/270 DS1/100 T182.5> ONTD
Screen Negative
AmnioUS Nothing
10-14
16-19
Results 18-20
Timeline weeks
Decision Making
20+ wks
+
=DR: 94-96%FPR: 5%
Advantages• Increases detection rate• Decreases false positive rate (fewer tests
and fewer procedure related losses)
Disadvantages• Long wait time for result• Unable to utilize CVS and early detection • Late GA by the time amnio results final
Contingent
First Trimester Screening
High risk Low Risk Intermediate
Triple Screening IntegrationOffer CVS
High riskLow Risk
US and AmnioStop
Advantages• Increase detection rate 90%• Decrease FPR 2%• Reduce the number of amnios
performed in low risk pregnancies
Disadvantages
•New (limited data)•Hard to determine uptake•Offered at few institutions
RISK OF ANEUPLOIDY BASED ON GA AND ANOMALY
3D UltrasoundFetal Face24 weeks Gestation
Fetal MRI
FETOSCOPY
Amnion (stuck twin)
Umbilical cord
QUESTIONS ??